[Treatment of intra- and postoperative cardiac tachyarrhythmias with the new calciumantagonist Ro 11-1781 (author's transl)].
30 patients with cardiac tachyarrhythmias were treated intra- and postoperatively with the new calciumantagonist Ro 11-1781. Atrial fibrillation, paroxysmal supraventricular tachycardia, supraventricular and ventricular extrasystoles and atrial tachycardia were the main indications. A good antiarrhythmic effect was noticed, provided that a dose of not less than 1 mg/kg was given. The mean fall of blood pressure was 4%, the maximal fall 15%.
D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy; D002118:Calcium / Q000037:antagonists & inhibitors*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006801:Humans; D007431:Intraoperative Complications / Q000188:drug therapy; D008875:Middle Aged; D010647:Phenyl Ethers / Q000627:therapeutic use; D011183:Postoperative Complications / Q000188:drug therapy; D013610:Tachycardia / Q000188:drug therapy*; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy
D006571:Heterocyclic Compounds; D010647:Phenyl Ethers; D002118:Calcium
Erfahrungen über den intra- und postoperativen Einsatz des neuen Kalziumantagonisten Ro 11-1781 bei tachykarden Herzrhythmusstörungen.